Lupin Launches Generic Mirabegron in US

By By Rediff Money Desk, MUMBAI
Apr 22, 2024 12:01
Lupin launches generic Mirabegron extended-release tablets (25 mg) in the US market, approved by USFDA. The drug treats overactive bladder.
New Delhi, Apr 22 (PTI) Drug maker Lupin on Monday said it has launched Mirabegron extended-release tablets (25 mg) in the US market.

The Mumbai-based drug maker has introduced the medication after receiving an approval from the US Food and Drug Administration (USFDA), Lupin said in a statement.

The company's product is a generic equivalent of Astellas Pharma Global Development, Inc's Myrbetriq extended-release tablets, it added.

Mirabegron extended-release tablets are used to treat certain bladder problems including overactive bladder.

Lupin shares were trading 3.38 per cent up at Rs 1,599.35 apiece on the BSE.
Read More On:
lupinmirabegrongeneric drugusfdaoveractive bladder
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

India Logistics Cost Down to 9%: Gadkari

Nitin Gadkari says India has met its target to reduce logistics cost to 9% of GDP due...

Coal Mining: Panel Urges Faster Green Clearances

Parliamentary panel urges faster environmental & forest clearances for coal mining...

DCM Shriram & Bayer Crop Science Collaboration

DCM Shriram and Bayer Crop Science partner to explore agricultural opportunities in...

Silver Price Soars to Rs 1.92 Lakh/kg on Global...

Silver prices surge Rs 11,500 to Rs 1.92 lakh/kg in Delhi amid strong global cues. Gold...

Urea Fixed Costs to Rise for Manufacturers

Govt plans to raise fixed costs for urea makers by year-end. Decision expected soon,...

Bullion Rates Today: Gold & Silver Prices

Check today''s closing bullion rates in Bengaluru. Gold (22K & 24K) prices per gram and...

Bank of India Raises Rs 2,500 Cr via Tier II Bonds

Bank of India (BoI) raised Rs 2,500 crore through Basel III-compliant Tier II bonds at...

Cipla Launches Obesity & Diabetes Drug Yurpeak

Cipla launches Yurpeak (tirzepatide), a weekly injectable for obesity and type-2...

Sebi Eases KYC for NRIs, Removes Physical Presence

Sebi relaxes re-KYC for NRIs, removing physical presence requirement for digital...

OPTCL & NABARD Pact: Power Boost in Odisha

OPTCL and NABARD sign MoU for power infrastructure development in Odisha. NABARD...

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2025 Rediff.com